Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

Recruiting now · Not applicable

Conditions studied: Ovarian Cancer Stage III, Ovarian Cancer Stage IV

In brief

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

Key facts

Study ID

NCT06017557

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

151

Starts

2023-01-02

Expected to finish

2026-09-01

Last updated by the study team

2025-12-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
• Patients fit for cytoreductive surgery
• Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
• Patients selected for interval cytoreductive surgery after NACT

You may not qualify if…

• Patients with pre-operative Stage I-II disease confined to the pelvis
• Patients unfit for surgery
• Lack of information about patients' surgical outcomes and clinicopathological characteristics
• LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)

Where it is running

• Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica — Roma, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.